menu

Potassium Binders in Heart Failure: Who, When, and How

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Potassium Binders in Heart Failure: Who, When, and How

close
0.25 credits
15 minutes
Potassium Binders in Heart Failure: Who, When, and How
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Clinicians often struggle to optimize guideline-directed medical therapy in patients with heart failure and frequently lower RAASi therapies in response to episodes of hyperkalemia, which translates into an increased risk for poor outcomes. But what if there was a better way to lower potassium levels so that these patients could reach those target doses?

    This activity will cover the screening and monitoring strategies for hyperkalemia in patients with heart failure as well as how to utilize newer potassium binders to maximize guideline-recommended RAASi therapy.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty

    Ileana L. Piña, MD, MPH, FAHA, FACC
    Professor of Medicine
    Wayne State University
    Detroit, MI

    Consulting Fees: Novartis, Relypsa 

    Patrick Rossignol, MD, PhD
    Professor
    Université de Lorraine
    Nancy, FRANCE 

    Consulting Fees: Ablative Solutions, AstraZeneca, Boehringer Ingelheim, Corvidia, Novartis, Relypsa, Sequana, Vifor Pharma
    Ownership Interest: CardioRenal 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop screening and monitoring strategies for hyperkalemia in patients with heart failure.
    • Apply evidence-based data surrounding newer potassium binders as a strategy for maximizing guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
  • Target Audience

    This activity is designed to meet the educational needs of heart failure specialists, cardiologists, primary care physicians, nephrologists, and all other allied healthcare professionals involved in the diagnosis, treatment, and care of heart failure.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Clinicians often struggle to optimize guideline-directed medical therapy in patients with heart failure and frequently lower RAASi therapies in response to episodes of hyperkalemia, which translates into an increased risk for poor outcomes. But what if there was a better way to lower potassium levels so that these patients could reach those target doses?

    This activity will cover the screening and monitoring strategies for hyperkalemia in patients with heart failure as well as how to utilize newer potassium binders to maximize guideline-recommended RAASi therapy.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty

    Ileana L. Piña, MD, MPH, FAHA, FACC
    Professor of Medicine
    Wayne State University
    Detroit, MI

    Consulting Fees: Novartis, Relypsa 

    Patrick Rossignol, MD, PhD
    Professor
    Université de Lorraine
    Nancy, FRANCE 

    Consulting Fees: Ablative Solutions, AstraZeneca, Boehringer Ingelheim, Corvidia, Novartis, Relypsa, Sequana, Vifor Pharma
    Ownership Interest: CardioRenal 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop screening and monitoring strategies for hyperkalemia in patients with heart failure.
    • Apply evidence-based data surrounding newer potassium binders as a strategy for maximizing guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
  • Target Audience

    This activity is designed to meet the educational needs of heart failure specialists, cardiologists, primary care physicians, nephrologists, and all other allied healthcare professionals involved in the diagnosis, treatment, and care of heart failure.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/11/20